BioPharma Drive: Drug Pricing

SEPTEMBER 20, 2023

Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

Targeted Protein Degradation 274

Targeted Protein Degradation Drugs Pharmaceuticals Research 274

Drug Target Review

JULY 6, 2023

Unlike traditional drug discovery, which focuses on inhibiting or activating proteins, TPD offers a more precise and efficient way to alter cellular pathways. 1 The concept of TPD was first demonstrated with a heterobifunctional small molecule to degrader a protein of interest in the early 2000s. How does TPD work?

Targeted Protein Degradation 98

Targeted Protein Degradation Small Molecule Clinical Trials Science 98

The Pharma Data

DECEMBER 16, 2020

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.

Targeted Protein Degradation 40

Targeted Protein Degradation Bioinformatics Disease Drugs 40

Sygnature Discovery

SEPTEMBER 25, 2023

Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation. Its staff of over 1,000, which includes 900 scientists, partners with global pharma, biotech and NFP organisations.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

Drug Target Review

JULY 5, 2024

14 However, pharma, biotech companies and contract research organisations (CROs) are actively exploring the potential to scale up organoid screening capabilities ( Table 1 ). Pharmaceutics. Pharmaceutics. A significant challenge for the field is incorporating 3D models into high-throughput platforms. Nature Neuroscience.

Targeted Protein Degradation 64

Targeted Protein Degradation Drugs Disease FDA Approval 64

The Pharma Data

SEPTEMBER 15, 2020

We are happy to support their scientific efforts as they tackle complex research challenges that potentially address critical unmet medical needs for patients. Our Degradomer® class of targeted protein degraders expands on the Trilomer® concept, allowing highly specific degradation of disease-causing proteins.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52